Veteran Investor Eli Casdin Weighs in on Diagnostics as High-Value Information

article image

Diagnostics investor Eli Casdin highlights some bright spots in a murky field, as PAMA uncertainty lifts, and liquid biopsy data is a draw at ASCO. Plus, Wall Street’s initial take on PAMA’s final rule.

Events in June revealed the Jekyll & Hyde nature of today’s diagnostics world, even as they pointed to modest progress in the field. The presentation of terrific information at major meetings alternated with discussions of the ever-present barriers. 


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: